NCT01184053View on ClinicalTrials.gov

Trisenox® in Women With Metastatic Endometrial Cancer

PHASE2TerminatedINTERVENTIONAL

Enrollment

3

Participants

Timeline

Start Date

March 31, 2010

Primary Completion Date

March 31, 2012

Study Completion Date

March 31, 2012

Conditions

Endometrial Carcinoma

Interventions

DRUG

Arsenic trioxide

Arsenic trioxide - 0.25 mg/kg/day for 5 consecutive days, every 4 weeks.

Trial Locations (1)

27599

North Carolina Cancer Hosptial, UNC, Chapel Hill

Sponsors

Collaborators (1)

All Listed Sponsors

collaborator

Cephalon

INDUSTRY

lead

UNC Lineberger Comprehensive Cancer Center

OTHER